Elevation Oncology strengthens cancer drug pipeline as cash reserves hit $93m
Elevation Oncology, Inc. has released its financial results for the fourth quarter and full-year 2024, outlining significant progress in its pipeline of targeted cancer therapies. ... Read More
Eli Lilly’s Cyramza fails to improve survival in gastric cancer trial despite meeting initial goal
In a recent announcement, Eli Lilly and Company disclosed that its phase 3 RAINFALL trial of the drug Cyramza (ramucirumab) for the treatment of HER2-negative ... Read More